Skip to main content
What types of page to search?

Alternatively use our A-Z index.

Publications

What type of publication do you want to show?

2022

An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

Wysocki, O., Zhou, C., Rogado, J., Huddar, P., Shotton, R., Tivey, A., . . . Co-Care, E. S. M. O. (2022). An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. Cancers, 14(16). doi:10.3390/cancers14163931

DOI
10.3390/cancers14163931
Journal article

2021

Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome

Lee, R. J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., . . . Armstrong, A. C. (2021). Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome. ESMO OPEN, 6(1). doi:10.1016/j.esmoop.2020.100005

DOI
10.1016/j.esmoop.2020.100005
Journal article

Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.

Bhogal, T., Khan, U. T., Lee, R., Stockdale, A., Hesford, C., Potti-Dhananjaya, V., . . . Palmieri, C. (2021). Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.. Leukemia & lymphoma, 1-16. doi:10.1080/10428194.2021.1876865

DOI
10.1080/10428194.2021.1876865
Journal article

2020

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.

Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.. Haematologica, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805

DOI
10.3324/haematol.2019.230805
Journal article

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial

Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial. HAEMATOLOGICA, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805

DOI
10.3324/haematol.2019.230805
Journal article

2018

2017

2015

PEGylated IFNβ-1a in the treatment of multiple sclerosis.

Khan, U. T., Tanasescu, R., & Constantinescu, C. S. (2015). PEGylated IFNβ-1a in the treatment of multiple sclerosis.. Expert opinion on biological therapy, 15(7), 1077-1084. doi:10.1517/14712598.2015.1053206

DOI
10.1517/14712598.2015.1053206
Journal article

2014

2012

A Novel, Safe Way of Removing Non-Deflatable Bladder Catheter

Khan, Z., Tahir Khan, U., Khan, I., & Naeem Khan, T. (2012). A Novel, Safe Way of Removing Non-Deflatable Bladder Catheter. Open Journal of Urology, 02(04), 243-245. doi:10.4236/oju.2012.24044

DOI
10.4236/oju.2012.24044
Journal article